GENIE Registry Identifies Cancer Types Enriched with KRASG12C Somatic Mutations
The analysis also illustrates differences according to sex and ethnic group
Oncology News
ESMO oncology news aims to keep you up to date with the developments that affect you and your daily practice.
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
1533 results
Adjuvant Therapy with Oxaliplatin Added to Fluoropyrimidine Improves Survival in Patients with MSI/dMMR Stage III Colon Cancer
The ACCENT database analysis supports flouropyrimidine plus oxaliplatin as standard-of-care adjuvant treatment for patients with MSI/dMMR stage III colon cancer
Newly Developed RSClin Provides Prognostic Information in HR-positive, HER2-negative Early Breast Cancer
The RSClin integrates genomic and clinical features, thereby offering the potential to guide the use of adjuvant chemotherapy with greater precision
Chemotherapy Administered for the First Diagnosed Testicular Cancer Reduces the Risk of Metachronous Contralateral Testicular Cancer Occurrence
Retrospective study indicates that the age at first testicular cancer diagnosis and treatment intensity influence the second testicular cancer risk
Palbociclib Plus Endocrine Therapy Does Not Improve PFS over Capecitabine in HR-positive, HER2-negative Aromatase Inhibitor Resistant Metastatic Breast Cancer
Head to head comparison demonstrates progression-free survival advantage with chemotherapy over palbociclib plus endocrine therapy
Prognostic Value of Longitudinal ctDNA Assessment in Oesophageal Cancer
Liquid biopsy findings from a prospective Oesophageal Cancer Classification and Molecular Stratification Consortium study
FDA Approves Selinexor for Refractory or Relapsed Multiple Myeloma
Efficacy of selinexor in combination with bortezomib and dexamethasone was evaluated in the BOSTON study
FDA Approves Relugolix for Advanced Prostate Cancer
Efficacy was evaluated in HERO study
FDA Approves Osimertinib as Adjuvant Therapy for NSCLC with EGFR Exon 19 Deletions or Exon 21 L858R Mutations
Efficacy was demonstrated in ADAURA study
FDA Approves Margetuximab for Metastatic HER2-positive Breast Cancer
Evidence for efficacy was evaluated in SOPHIA study
EMA Recommends Granting a Marketing Authorisation for Fedratinib
JAK inhibitor is intended for the treatment of primary myelofibrosis and of myelofibrosis secondary to polycythaemia vera or essential thrombocythaemia
EMA Recommends Granting a Marketing Authorisation for Tucatinib
It is intended for the treatment of HER2-positive locally advanced or metastatic breast cancer